Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $1,061 | $986 | $2,681 | $3,239 |
Gross Profit | 451 | 312 | 1,906 | 2,558 |
EBITDA | -25,804 | -22,046 | -25,222 | -18,390 |
EBIT | -26,414 | -22,720 | -25,997 | -19,071 |
Net Income | 5,061 | -34,863 | -27,892 | -18,041 |
Net Change In Cash | 1,061 | 986 | 2,681 | 3,239 |
Free Cash Flow | -19,500 | -22,815 | -22,665 | -20,348 |
Cash | 45,148 | 24,367 | 135,774 | 70,429 |
Basic Shares | 3,092 | 3,092 | 12,672 | 43,496 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $15,529 | $13,907 | $4,359 | $-10,548 |
Gross Profit | 12,460 | 13,907 | 4,359 | -10,548 |
EBITDA | -84,358 | -93,905 | -124,543 | -94,509 |
EBIT | -87,427 | -97,580 | -128,321 | -97,834 |
Net Income | -87,679 | -96,046 | -128,332 | -108,543 |
Net Change In Cash | 15,529 | 13,907 | 4,359 | -10,548 |
Cost of Revenue | -105,518 | -33,963 | 150,840 | |
Free Cash Flow | -79,016 | -80,332 | -116,554 | -76,327 |
Cash | 135,774 | 81,347 | 186,816 | 220,383 |
Basic Shares | 64,260 | 42,695 | 39,855 | 34,177 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.03 |
2024-03-31 | -$0.22 |
2023-12-31 | -$0.22 |
2023-09-30 | -$0.41 |
